NYSE:IQV - Iqvia Stock Price, News & Analysis

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia Holdings Inc (NYSE:IQV) announced its earnings results on Wednesday, July, 24th. The medical research company reported $1.39 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.38 by $0.01. The medical research company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.70 billion. Iqvia had a net margin of 2.31% and a return on equity of 15.95%. The business's revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.29 earnings per share. View Iqvia's Earnings History.

Iqvia is scheduled to release their next quarterly earnings announcement on Monday, October 28th 2019. View Earnings Estimates for Iqvia.

Iqvia updated its FY19 earnings guidance on Wednesday, July, 24th. The company provided earnings per share guidance of $6.25-6.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.33. The company issued revenue guidance of $11.00-1.15 billion, compared to the consensus revenue estimate of $11.02 billion.

20 brokerages have issued 1-year price targets for Iqvia's stock. Their predictions range from $136.38 to $180.00. On average, they expect Iqvia's share price to reach $162.2576 in the next year. This suggests a possible upside of 5.9% from the stock's current price. View Analyst Price Targets for Iqvia.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 2 hold ratings, 16 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

Press coverage about IQV stock has trended positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Iqvia earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for Iqvia.

Iqvia saw a drop in short interest in July. As of July 31st, there was short interest totalling 2,474,900 shares, a drop of 12.4% from the June 30th total of 2,824,800 shares. Based on an average daily trading volume, of 1,270,000 shares, the short-interest ratio is presently 1.9 days. Approximately 1.4% of the shares of the company are short sold. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS) and Eloxx Pharmaceuticals (ELOX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), Micron Technology (MU), NIC (EGOV), Zoetis (ZTS) and Workday (WDAY).

Iqvia's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.35%), BlackRock Inc. (6.86%), BlackRock Inc. (6.86%), Janus Henderson Group PLC (1.85%), Janus Henderson Group PLC (1.85%) and AQR Capital Management LLC (1.43%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Dennis B Ph D Gillings, Group Holdings (Sbs) Advis Tpg, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Morgan Stanley, AQR Capital Management LLC, Eminence Capital LP, Bank of New York Mellon Corp, Quest Capital Management Inc. ADV, AMF Pensionsforsakring AB and Highline Capital Management L.P.. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer and W Richard Staub. View Insider Buying and Selling for Iqvia.

IQV stock was acquired by a variety of institutional investors in the last quarter, including Investec Asset Management LTD, Nuveen Asset Management LLC, Egerton Capital UK LLP, BlackRock Inc., BlackRock Inc., Putnam Investments LLC, Janus Henderson Group PLC and Janus Henderson Group PLC. View Insider Buying and Selling for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $153.15.

Iqvia has a market capitalization of $30.00 billion and generates $10.41 billion in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.View Additional Information About Iqvia.

The official website for Iqvia is http://www.iqvia.com/.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]